天美生物美股招股说明书(2023-01-27版)

424B51form424b5.htm FiledPursuanttoRule424(b)(5)RegistrationNo.333-267116 ProspectusSupplement (toProspectusDatedNovember22,2022) 2,750,000OrdinaryShares BonNaturalLifeLimited Thisprospectussupplementrelatestotheofferandresalebycertainsellingstockholdersofanaggregate2,750,000ordinaryshares,$0.0001parvaluepershare(the“OrdinaryShares”),ofBonNaturalLifeLimited,allofwhichwereissuedbyusinaprivateplacementtransactionpursuanttosubscriptionagreements(eacha“SubscriptionAgreement”)atapurchasepriceof$0.80pershare.Theholdersofthesharesareeachreferredtohereinasa“SellingStockholder”andcollectivelyasthe“SellingStockholders.” TheSellingStockholders,ortheirrespectivetransferees,pledgees,doneesorothersuccessors-in-interestmayselltheOrdinarySharesthroughpublicorprivatetransactionsatprevailingmarketprices,atpricesrelatedtoprevailingmarketpricesoratprivatelynegotiatedprices.TheSellingStockholdersmaysellany,allornoneofthesecuritiesofferedbythisprospectus,andwedonotknowwhenorinwhatamounttheSellingStockholdersmayselltheirShareshereunder.WeprovidemoreinformationabouthowaSellingStockholdermaysellitsSharesinthesectiontitled“PlanofDistribution”onpageS-50. WeareregisteringtheOrdinarySharesonbehalfoftheSellingStockholders,tobeofferedandsoldbythemfromtimetotime.WewillnotreceiveanyproceedsfromthesaleoftheOrdinarySharesbytheSellingStockholdersintheofferingdescribedinthisprospectus.WehaveagreedtobearalloftheexpensesincurredinconnectionwiththeregistrationoftheOrdinaryShares.TheSellingStockholderswillpayorassumediscounts,commissions,feesofunderwriters,sellingbrokersordealermanagersandsimilarexpenses,ifany,incurredforthesaleoftheOrdinaryShares. OurOrdinarySharesarelistedontheNasdaqCapitalMarket,or“Nasdaq,”underthesymbol“BON.”OnJanuary252023,thelastreportedsalepriceofourOrdinarySharesonNasdaqwas$1.22pershare.TheaggregatemarketvalueofouroutstandingOrdinarySharesheldbynon-affiliates,orpublicfloat,asofJanuary252023,wasapproximately$11,743,116whichwascalculatedbasedonOrdinarySharesheldbynon-affiliatesandthepriceof$1.22pershare,whichwastheclosingpriceofourOrdinarySharesonNasdaqonJanuary25,2023. InvestinginourOrdinarySharesinvolvesahighdegreeofrisk.Beforemakinganinvestmentdecision,pleasereadtheinformationundertheheading“RiskFactors”beginningonpageS-18ofthisprospectussupplementandriskfactorssetforthinourmostrecentannualreportonForm20-F,inotherreportsincorporatedhereinbyreference,andinanapplicableprospectussupplementundertheheading“RiskFactors.”NeithertheSecuritiesandExchangeCommissionnoranystatesecuritiescommissionhasapprovedordisapprovedtheissuanceofthesesecuritiesorpassedupontheadequacyoraccuracyofthisprospectussupplementortheaccompanyingprospectus.Anyrepresentationtothecontraryisacriminaloffense. InvestorsinourOrdinarySharesarenotpurchasingequitysecuritiesinoursubsidiariesthathavesubstantivebusinessoperationsinChinabutinsteadarepurchasingequitysecuritiesofaCaymanIslandsholdingcompany,BonNaturalLifeLimited.WeareaCaymanIslandsholdingcompanythatconductsallofouroperationsandoperatesourbusinessinChinathroughourPRCsubsidiaries.Suchstructureinvolvesuniqueriskstoinvestorsinourordinaryshares.ReferencesinthisProspectusto“BonNaturalLife,”“theCompany,”“we,”“us,”“ourcompany”or“our”aretoBonNaturalLifeLimitedaCaymanIslandscorporation,togetherwithitssubsidiariescollectively.Pleasesee“CommonlyDefinedTerms”fornamingconventionsregardingoursubsidiarycompanies.AlthoughwecontrolourPRCoperatingsubsidiariesthroughourHongKongandPRCsubsidiaries,investorsinthisofferingmayneverholdequityinterestsdirectlyinouroperatingentities.Inaddition,BonNaturalLifeLimited,theCaymanIslandscompanysellingsecuritiesinthisoffering,doesnotholdequityinterestsinthePRCoperatingsubsidiariesdiscussedherein.Instead,BonNaturalLifeownsaHongKongsubsidiary,whichinturnownstwoPRCsubsidiaries,whichinturnowntheoperatingPRCcompaniesdiscussedinthisProspectus.Pleaserefertotheorganizationalchartonpage1ofthisProspectus. Weoriginallycarriedoutourbusinessthroughavariableinterestentitystructure.EffectiveNovember1,2021,weterminatedtheoriginalVIEcontractualagreementsandcompletedthereorganizationofourcorporatestructureandallofouroperationsarecurrentlyconductedinChinathroughourwholly-ownedsubsidiaries. WedonotcurrentlyengageinanybusinesseswhereforeigninvestmentisrestrictedunderChineselaw,astheCompanyanditssubsidiariesdonotparticipateinanysectororindustrythatis“restricted”or“prohibited”fromforeigninvestmentunderthe“NegativeList”publishedbyChina’sNationalDevelopmentandReformCommissionandtheMinistryofCommerce.ThemostrecentversionofthePRC’sNegativeList,TheSpecialAdministrativeMeasures(NegativeList)forForeignInvestmentAccess(2021Edition)ortheNegativeList2021,lists31industriesinwhichforeigninvestmentisrestrictedorprohibited.Ourbusinessactivities,whicharefocusedontheproductionoffragrancecompounds,healthsupplements,andbioactivefoodingredients,arenotincludedwithintheindustriesandfieldslistedintheNegativeList2021.ForafullerexplanationofChina’s“NegativeList,”pleaseseeourAnnualReportonForm20-FfiledJanuary31,2022atpage47under“Regula